Antisense Editorial Office to Move

Abstract

FOR THE LAST DECADE, the editorial office of the Antisense & Nucleic Acid Drug Development journal has been at the University of Iowa. During this time, the antisense field has undergone dramatic development, capped by the approval of the first antisense drug by the Food and Drug Administration and by the progressive increase in the number of antisense oligonucleotides used in human clinical trials. Some of these other antisense oligonucleotides are currently in phase III human clinical trials and seem likely to be approved by the FDA within the next few years. In addition to antisense oligonucleotides, therapeutic oligonucleotides that work through nonantisense mechanisms have also entered the clinic. Immune stimulatory oligonucleotides with CpG motifs are currently being evaluated in more than ten human clinical trials as immune activators for treatment or prevention of infectious diseases, cancer, and allergies. In order to promote the further clinical development of these CpG oligos, I will be taking a leave of absence from the University of Iowa and moving to Boston to join the Coley Pharmaceutical Group which is seeking to commercialize CpG technology. I will continue to run the editorial office of Antisense & Nucleic Acid Drug Development from the Coley Pharmaceutical Group headquarters. For our readers, there should be no apparent change in the functioning of the journal. However, we ask our authors and reviewers to note the new address of the editorial office and to make sure that correspondence and manuscripts are sent to this new address, effective immediately. It is: 93 Worcester Street, Suite 101, Wellesley, MA 02481. The phone number is: (781) 431-6400. The fax number is: (781) 4316403. The e-mail address is: akrieg@coleypharma.com We trust that the next decade of Antisense & Nucleic Acid Drug Development will be even more exciting than the last one!